Home Research Broadcast Forums Information FinancialWire® NewsFeed Companies
Investrend Story |
You are here: Welcome Guest ! Please Login or Register  
Bioenvision, Inc.( BIV ) InvestorPower™
Bioenvision's primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Oncology, Inc.); Modrenal® (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer); and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been approved for certain indications in the U.S. CONTACT INFO:
Bioenvision, Inc. David P. Luci,
Phone: 212/750-6700
Fax: N/A

www.bioenvision.com
Company Profile
Analyst:  N/A
Price Target:  N/A
Time Horizon:  N/A
Research Established:  N/A
Rating:  N/A   ?
 
Click to trade 24/7
Charts


Charts courtesy of http://portals.wallstreettape.com



Company Search
Company Research
Company Broadcasts
FinancialWire
Company Events
Events not found
Links for this Company
" NewsAlert.com
" YahooFinance News
" WallStreetCity
" Bloomberg
" MSN Money
" CBS MarketWatch
" Nasdaq News
" Multex Investor
" PrimeZone
" CNET Investor
" pcQuote
" Business Wire
" PR Newswire
" EDGAR
" SEDAR
Free Real-Time Quotes
Sign Up / Login
Free Trial
Descriptions
Take the tour
  ABOUT US | CONTACT US | CALENDAR | SITE SEARCH     |    © 2004, Investrend.com, Inc.